CMS Innovation Center Builds Infrastructure
This article was originally published in The Pink Sheet Daily
Five divisions include a "seamless" care group to oversee accountable care organizations and similar delivery models.
You may also be interested in...
CMS should look for ways to ensure that financial incentives for Medicare accountable care organizations do not promote inappropriate shifts in prescribing from the Part B benefit to Part D, biotech and clinician groups urge in comments filed with the agency June 6.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.